Metrics as of 10/17/2026, 02:41 AM (Berlin time), refresh in progress.
Atai Beckley Stock
Atai Beckley Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Srinivas G. Rao
- Employees
- 99
- Market cap
- $2.7 B
- IPO
- 18/06/2021
Atai Beckley Inc. is a clinical biopharmaceutical company focused on the discovery and commercialization of innovative therapeutic solutions for various mental health disorders. Operating in the healthcare/biotechnology sector, the company operates in the US, Germany, and Canada, with its headquarters located in New…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Atai Beckley stock: price history
1D
+0.0%
1W
-0.5%
1M
+1.7%
6M
+99.2%
YTD
+79.7%
1Y
+59.8%
2Y
+488.0%
5Y
-55.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~7% stronger price swings than usual
Atai Beckley stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Atai Beckley Inc. is a clinical biopharmaceutical company specializing in the discovery and commercialization of innovative therapies for various mental health disorders. The company is developing a pipeline of active pharmaceutical ingredients for treating conditions such as treatment-resistant depression, schizophrenia, and anxiety disorders. Research currently focuses on multiple substances in clinical phases 2 and 2b, including serotonergic psychedelic compounds and neuromodulators. With a focus on intellectual property development, the company is working toward market readiness of its therapeutic solutions for the global healthcare market.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Atai Beckley
Analyst assessment of Atai Beckley
PRICE TARGET LOW
US$7.45
CONSENSUS
US$7.69
MEDIAN
US$7.50
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
0
BUY
8
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Hold
As of: 12/08/2026
Atai Beckley stock metrics
P/E
-2.53
P/B
15.03
EV/EBITDA
-3.77
RETURN ON EQUITY
-18.4%
NET MARGIN
-1,908.7%
DEBT/EQUITY
0.02
DIVIDEND YIELD
91.8%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
54.3%
FLOAT SHARES
201,024,101
AVG. DAILY VOLUME (30D)
11,242,909
Insider transactions (SEC)
Craig Kevin James
Angermayer Christian
Smiley Andrea Heslin
Kalali Amir H
Short Glenn Frank
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.0%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Atai Beckley stock
What does Atai Beckley do?
Atai Beckley Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Srinivas G. Rao, the company employs around 99 people.
The IPO was on 18/06/2021; the stock trades on NASDAQ under the ticker ATAI.
What do analysts say about Atai Beckley stock?
8 analysts rate the stock, the consensus is Hold (as of 12/08/2026).
The average price target is US$7.69, ranging from US$7.45 to US$8.00, with a median of US$7.50.
This is an external assessment, not a statement by Market Jury.
When does Atai Beckley report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Atai Beckley pay a dividend?
Yes. The last dividend was US$6.75 per share.
The dividend yield is 91.8% (as of 30/06/2026).
Which stocks are comparable to Atai Beckley?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Atai Beckley stock analyzed?
Clicking "Analyze stock" lets five strategies assess Atai Beckley against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.